Virax Biolabs COO Boosts Confidence with 20,000 New Stock Options Amid Strategic Turnaround
Virax Biolabs COO’s 20,000‑option grant shows insider confidence in its turnaround plan, highlighting potential upside amid biotech, diagnostics, and PPE growth prospects.
2 minutes to read